You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)治療呼吸領域的創新藥提試驗藥申請獲FDA受理
阿思達克 10-08 12:12
中生製藥(01177.HK)公佈,就自主研發的創新藥TCR1672,已向美國食品藥品監督管理局(FDA)提交試驗用新藥申請,並獲得受理。 該產品爲二代高選擇性的P2X3受體拮抗劑,目前主要應用於治療呼吸領域的難治性慢性咳嗽(RCC)成年患者及疼痛領域的子宮內膜異位症等複雜性內臟痛患者。 公司表示,目前全球尚未有P2X3抑制劑獲批,相關產品存在巨大的市場潛力,料將進一步豐富集團在呼吸領域和疼痛領域的創新產品管線。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account